Clinical Trials
FDA Decision on New Once-Daily Pill Expected Mid-2026
Tavapadon is a once-daily pill from AbbVie that targets dopamine receptors differently than older Parkinson's medications. In the Phase 3 TEMPO trials, people who took tavapadon along with their existing levodopa gained about one extra hour of good mobility each day. It also caused fewer side effects like sleepiness or impulsivity. AbbVie submitted the drug to the FDA in September 2025; a decision could come by mid-2026. *
apdaparkinson.orgWorld's Largest Parkinson's Trial Now Recruiting Across UK
The Edmond J. Safra Accelerating Clinical Trials in Parkinson's (EJS ACT-PD) launched in October 2025 as the largest Parkinson's trial ever attempted — a £26 million study across 40+ UK hospitals recruiting up to 1,600 participants. Unlike traditional trials that test one drug at a time, this one tests multiple treatments at once, potentially cutting years off the time needed to find effective disease-modifying treatments. *
vai.orgStem Cell Therapy Enters Final Large-Scale Trial
A stem cell therapy called bemdaneprocel, made by Bayer subsidiary Blue Rock Therapeutics, has entered Phase 3 testing — the final stage before seeking approval. The treatment transplants dopamine-producing neurons made from stem cells directly into the brain. Earlier smaller trials showed the implanted cells survived and integrated. If it works, it would be the first therapy that repairs Parkinson's underlying damage. *
apdaparkinson.org
Breakthrough Treatments
Adaptive Brain Stimulator Approved for Parkinson's
The FDA approved a new brain implant in February 2025 that watches your brain activity in real time and automatically adjusts its electrical pulses to prevent stiffness and shaking before it starts. Unlike older stimulators that blast constant electricity, this one knows when to kick in and when to back off — especially helpful when medication wears off. It's now available nationwide through Medtronic devices at major movement disorder centers. *
ucsf.eduNew Drug Targets Parkinson Progression in Final Test Phase
Roche's prasinezumab moved into Phase III clinical trials — the final stage before FDA approval — after showing it can target the toxic proteins that destroy brain cells in Parkinson's. If it works, it would be one of the first treatments that actually slows the disease's progress, not just masks symptoms. Phase III will test it in thousands of patients over several years. *
michaeljfox.orgOnce-Daily Pill Targets Dopamine with Fewer Side Effects
AbbVie submitted a new drug called tavapadon to the FDA in late 2025. It targets D1 and D5 brain receptors instead of D2/D3, which in trials led to fewer problems with sleepiness, impulsivity, and hallucinations. The TEMPO trials showed it helped both newly diagnosed patients and those already on levodopa who experience wearing-off periods. *
apdaparkinson.org
Lifestyle Interventions
Updated Exercise Guidelines Emphasize Consistency
The Parkinson's Foundation and the American College of Sports Medicine released updated exercise guidelines in 2026, emphasizing that moderate-to-vigorous aerobic exercise — like brisk walking or cycling — improves motor symptoms, mood, digestion, and thinking skills. Experts recommend at least 150 minutes per week, tailored to each person's abilities. The key is starting early and staying consistent. *
acsm.orgMediterranean Diet with MCT Oil May Ease Motor Symptoms
A 2026 clinical trial tested two versions of a Mediterranean-style diet in people with Parkinson's. The version that added MCT (medium chain triglyceride) oil led to measurable improvements in how patients reported their motor symptoms. Interestingly, the group that achieved ketosis didn't show the same benefit, suggesting the MCT oil itself may be what's helpful — not the metabolic state. *
pubmed.ncbi.nlm.nih.govDeep Sleep Research Offers Hope for Slowing Parkinson's
Oregon Health & Science University received $4 million in 2025 to study the link between REM sleep behavior disorder (RBD) and Parkinson's. In RBD, people physically act out their dreams because muscles aren't properly paralyzed during sleep. Researchers believe the brain's waste-clearance system — called the glymphatic system — is faulty in both conditions. If they can boost this system during deep sleep, it might help slow Parkinson's before symptoms even appear. *
news.ohsu.edu
Emerging Research
Gut Bacteria May Trigger Parkinson's Brain Changes
A December 2025 study found that certain gut bacteria — specifically sulfate-reducing bacteria — are found in higher numbers in people with Parkinson's and appear to trigger the same toxic protein buildup in the gut that later spreads to the brain. This gives scientists a new target to investigate: could changing gut bacteria someday help prevent or slow Parkinson's? This doesn't mean gut issues cause Parkinson's, but it adds to evidence that the gut and brain are connected. *
frontiersin.orgExperimental Drug Protects Brain Cells in Early Trial
Researchers at University College London, supported by Parkinson's UK, reported in 2025 that an experimental drug called HER-096 showed promising early results in its first human trial. Unlike current medications that replace dopamine, HER-096 is designed to protect the actual brain cells that produce dopamine from dying in the first place. Early trial participants tolerated the drug safely, and the compound reached its target in the brain. This is still very early research but represents a shift toward drugs that might slow or stop progression. *
parkinsons.org.uk
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.